AZD 1979

Drug Profile

AZD 1979

Alternative Names: AZD-1979

Latest Information Update: 01 Sep 2014

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Obesity therapies
  • Mechanism of Action Melanin-concentrating hormone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 28 Jul 2014 AstraZeneca terminates a phase I trial in healthy volunteers in USA after stopping criteria were reached (NCT02072993)
  • 31 Mar 2014 Phase-I clinical trials in Obesity (In volunteers) in USA (PO)
  • 25 Feb 2014 Preclinical trials in Obesity in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top